Identification of novel drug targets for primary open angle glaucoma and its potential side-effects by human plasma proteome
Four plasma proteins-SVEP1, TMEM190, ROBO1, and ENPP5-are identified as potential therapeutic targets for POAG through an MR approach. Phenome-wide MR analysis reveals that SVEP1, ROBO1, and ENPP5 are not associated with adverse effects, while TMEM190 is linked to nerve root and plexus disorders, as well as subarachnoid hemorrhage. Ticagrelor is proposed as a potential therapeutic drug for glaucoma by regulating SVEP1. These findings highlight the potential of plasma proteins as drug targets for POAG and provide valuable insights for further research.
Authors
- Deshui Jia (ORCID: https://orcid.org/0000-0002-2784-126X)
- Kaili Wu (ORCID: https://orcid.org/0000-0003-3606-683X)
- Liang Liang (ORCID: https://orcid.org/0000-0002-0082-5235)
- Meng Pan (ORCID: https://orcid.org/0000-0003-4947-9369)
- Shuang Song (ORCID: https://orcid.org/0000-0003-4075-2226)
Institutions
- Sun Yat-sen University (CN)
- China Three Gorges University (CN)
- Second Hospital of Yichang (CN)
- Yichang Central People's Hospital (CN)
- Shaanxi University of Chinese Medicine (CN)
Publication Details
- Journal
- International Journal of Ophthalmology
- Published
- 2025-07-18
- DOI
- https://doi.org/10.18240/ijo.2025.08.07
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gujarat Council on Science and Technology
- National Natural Science Foundation of China
- State Key Laboratory of Ophthalmology